Clinical trials: Hair Diseases
Androgenetic Alopecia
XVIE to Treat Androgenetic Alopecia (AGA)
This study tests whether XVIE, an investigational injectable product made from processed human amniotic fluid, is safe and may help regrow hair in adults with androgenetic alopecia (common pattern hair loss).
- Trial name
- NCT07482423
- Testing
- Decellularized allogeneic human amniotic fluid, Sodium chloride 0.9% injectable solution
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Androgenetic Alopecia
A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males
The overall purpose of this clinical investigation is to collect data to support a marketing application for over the counter use of the X5 HairLaser with an indication for hair growth.
- Trial name
- NCT02067260
- Testing
- X5 HairLaser
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Spencer Forrest, Inc.
Alopecia Areata
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).
- Trial name
- NCT07205159
- Testing
- FB102
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 32 people
- Sponsor
- Forte Biosciences, Inc.
Alopecia
Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain
Hair loss occurs commonly as a result of radiotherapy administered to the brain, and this can contribute to the distress and social isolation of patients with advanced cancer.
- Trial name
- NCT00801086
- Testing
- 7% (w/v) Tempol alcohol-based gel (MTS-01), alcohol-based gel
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Mitos Pharmaceuticals
Androgenetic Alopecia
Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia
The study is designed to evaluate safety and efficacy of PP405 in adult female participants with androgenetic alopecia
- Trial name
- AWAKENING (NCT07907783)
- Testing
- PP405 0.05% Topical Gel, Vehicle Topical Gel
- Volunteers
- 200 people
- Sponsor
- Pelage Pharmaceuticals, Inc.
Androgenetic Alopecia
Study of EPI-001 in Patients With Androgenetic Alopecia
This is a Phase I/IIa clinical study to evaluate the safety, tolerability, and preliminary efficacy of EPI-001 in patients with androgenetic alopecia.
- Trial name
- NCT07618195
- Testing
- EPI-001
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Epibiotech
Alopecia Areata
Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
This study will evaluate the safety and efficacy of CTP-543 on hair loss in adults with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03137381
- Testing
- CTP-543
- Where
- 13 sites in United States
- Volunteers
- 149 people
- Sponsor
- Concert Pharmaceuticals
Androgenetic Alopecia, Female Pattern Baldness
Clinical Study of Probiotic Treatment for Androgenetic Alopecia
The primary objective of the study is to assess the efficacy of DA-001 as an oral supplement for treatment of female pattern hair loss.
- Trial name
- NCT06484881
- Testing
- Daniel Alain Probiotic Treatment for Androgenetic Alopecia, Topical minoxidil 5%
- Sponsor
- Applied Biology, Inc.
Female Pattern Baldness, Hair Loss
ENERGI-F701 for Female Hair Loss Treatment
The objective of this study is to evaluate the efficacy and safety of ENERGI-F701 Solution in female subjects with hair loss.
- Conditions
- Female Pattern Baldness, Hair Loss, Alopecia
- Trial name
- NCT03351322
- Testing
- ENERGI-F701, Regaine
- Where
- Taiwan
- Volunteers
- 67 people
- Sponsor
- Energenesis Biomedical Co., Ltd.
Androgenetic Alopecia
Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia
The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.
- Trial name
- NCT07080931
- Testing
- 5% minoxidil foam
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Alopecia Areata, Alopecia Universalis
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
This is an open label study of ATI-502 Topical Solution for the treatment of AA, AU, and AT with the following goals: To assess the safety, tolerability, and efficacy of ATI-502 Topical Solution in subjects with AA, AU or AT…
- Conditions
- Alopecia Areata, Alopecia Universalis, Alopecia Totalis
- Trial name
- NCT03759340
- Testing
- ATI 502 0.46% Topical Solution
- Where
- 20 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aclaris Therapeutics, Inc.
Alopecia Areata
Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.
This clinical trial attempts to investigate the efficacy of LEO 124249 ointment in the treatment of alopecia areata on the eyebrows.
- Trial name
- NCT03325296
- Testing
- LEO 124249, Ointment vehicle
- Where
- 2 sites in Denmark
- Volunteers
- 13 people
- Sponsor
- LEO Pharma
Alopecia, Androgenetic, Baldness
A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.
This study will evaluate the safety and efficacy of PDFE-2304 compared with Minoxidil 5% in men with androgenic alopecia (AGA).
- Conditions
- Alopecia, Androgenetic, Baldness, Androgenetic Alopecia (AGA)
- Trial name
- NEOPILI-2A (NCT07011485)
- Testing
- Minoxidil 5% Topical Solution, PDFE-2304 Topical Solution
- Where
- India
- Volunteers
- 15 people
- Sponsor
- PDFE Pharma Innovations FZCO
Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)
Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
The main objectives of this study are to preliminarily evaluate the effectiveness of CG2001 in treating Chinese adult male AGA participants, determine the recommended dose for Phase III clinical studies, and evaluate the safety…
- Trial name
- NCT07076706
- Testing
- minoxidil + finasteride
- Where
- 8 sites in China
- Volunteers
- 110 people
- Sponsor
- Beijing Dayspring Pharmaceutical Technology Co., Ltd
Alopecia Areata
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
- Trial name
- BRAVE-AA2 (NCT03899259)
- Testing
- Baricitinib
- Where
- 96 sites in United States, Argentina and 8 more
- Volunteers
- 606 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata.
- Trial name
- BRAVE-AA1 (NCT03570749)
- Testing
- Baricitinib
- Where
- 75 sites in United States, Japan and 3 more
- Volunteers
- 784 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata
A Study of LAD603 in Adults With Alopecia Areata
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA).
- Trial name
- NCT07311564
- Testing
- LAD603
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Almirall, S.A.
Androgenetic Alopecia
Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment
Platelet rich plasma (PRP) therapy is a novel therapeutic modality that has seen broad applications for a number of medical indications including those in orthopedics, dentistry, and dermatology.
- Trial name
- NCT02591355
- Testing
- Autologous Platelet Rich Plasma, Saline solution injection
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Regen Lab SA